New CRISPR-Cas systems discovered

Ye, Hui; Patel, Dinshaw J.

doi:10.1038/cr.2017.21

Cited by 5 publications

(2 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, the development of smaller size Cas proteins has been under exploration to achieve more efficient encapsulating. [282][283][284][285] The primary requirements for safety are transient CRISPR/Cas expression and nanomaterials with acceptable biocompatibility. Second, the off-target effect of CRISPR/ Cas9 system is also worth considering.…”

Section: The Clinical Applications Of Crispr/cas9 Systemmentioning

confidence: 99%

“…High gene editing efficiency can be achieved by using nanomaterials capable of rapid lysosomal escape and nuclear localization. In addition, the development of smaller size Cas proteins has been under exploration to achieve more efficient encapsulating 282–285 . The primary requirements for safety are transient CRISPR/Cas expression and nanomaterials with acceptable biocompatibility.…”

Section: The Clinical Applications Of Crispr/cas9 Systemmentioning

confidence: 99%

See 1 more Smart Citation

Nanotechnology‐based CRISPR/Cas9 delivery system for genome editing in cancer treatment

Zhou,

Li,

et al. 2024

MedComm – Biomaterials and Applications

View full text Add to dashboard Cite

The clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated protein 9 (CRISPR/Cas9) systems initiate a revolution in genome editing, which have a significant potential for treating cancer. A significant amount of research has been conducted regarding genetic modification using CRISPR/Cas9 systems, and 33 clinical trials using ex vivo or in vivo CRISPR/Cas9 gene editing techniques have been carried out to treat cancer. Despite its potential advantages, the main obstacle to convert CRISPR/Cas9 technology into clinical genome editing applications is the safe and efficient transport of genetic material owing to various extra‐ and intracellular biological hurdles. We outline the characteristics of three forms of CRISPR/Cas9 cargos, plasmids, mRNA/sgRNA, and ribonucleoprotein (RNP) complexes in this review. The recent in vivo nanotechnology‐based delivery techniques for these three categories to treat cancer are then reviewed. In the end, we outline the prerequisites for effective and secure in vivo CRISPR/Cas9 delivery in clinical contexts and discuss challenges with current nanocarriers. This review offers a thorough overview of the CRISPR/Cas9 nano‐delivery system for the treatment of cancer, serving as a resource for the design and building of CRISPR/Cas9 delivery systems and offering fresh perspectives on the treatment of tumors.

show abstract

Section: The Clinical Applications Of Crispr/cas9 Systemmentioning

confidence: 99%

Section: The Clinical Applications Of Crispr/cas9 Systemmentioning

confidence: 99%